National Comprehensive Cancer Network

|
|
|
|
For Patients
About the NCCN Clinical Practice Guidelines in Oncology™
Recent Updates to NCCN Clinical Practice Guidelines in Oncology™
NCCN Categories of Evidence and Consensus
NCCN Guidelines Steering Committee
Submission Request to the NCCN Guidelines Panels
NCCN Guidelines Panels-Meeting Schedule
NCCN Drugs & Biologics Compendium™
About the NCCN Drugs & Biologics Compendium™
Compendium Chapters
No Longer Recommended Uses
JNCCN – The Journal of the National Comprehensive Cancer Network
Subscribe Now
FAQ
JNCCN Task Force Supplements

Clinical Recommendations

NCCN Drug and Biologics Compendium - Panel Members

Professionals


Go back to previous page

 

 

   
 

NCCN Drugs & Biologics Compendium

NCCN Acute Myeloid Leukemia (AML) Panel Members

These chapters of the NCCN Drugs & Biologics Compendium™ were developed directly from the NCCN Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia (AML).

These guidelines were developed by the following NCCN Acute Myeloid Leukemia (AML) Panel Members.

Margaret R. O'Donnell, MD/Chair*
City of Hope Comprehensive Cancer Center
Acute Myeloid Leukemia (AML)

Frederick R. Appelbaum, MD
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
Acute Myeloid Leukemia (AML)

Steven E. Coutre, MD
Stanford Comprehensive Cancer Center
Acute Myeloid Leukemia (AML)

Lloyd E. Damon, MD
UCSF Helen Diller Family Comprehensive Cancer Center
Acute Myeloid Leukemia (AML)

Harry P. Erba, MD, PhD
University of Michigan Comprehensive Cancer Center
Acute Myeloid Leukemia (AML)

James Foran, MD
University of Alabama at Birmingham Comprehensive Cancer Center
Acute Myeloid Leukemia (AML)

Jeffrey Lancet, MD
H. Lee Moffitt Cancer Center & Research Institute
Acute Myeloid Leukemia (AML)

Lori J. Maness, MD
UNMC Eppley Cancer Center at The Nebraska Medical Center
Acute Myeloid Leukemia (AML)

Guido Marcucci, MD
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute
Acute Myeloid Leukemia (AML)

Peter G. Maslak, MD
Memorial Sloan-Kettering Cancer Center
Acute Myeloid Leukemia (AML)

Michael Millenson, MD
Fox Chase Cancer Center
Acute Myeloid Leukemia (AML)

Joseph O. Moore, MD
Duke Comprehensive Cancer Center
Acute Myeloid Leukemia (AML)

Farhad Ravandi, MD
The University of Texas M. D. Anderson Cancer Center
Acute Myeloid Leukemia (AML)

Friedrich Schuening, MD
Vanderbilt-Ingram Cancer Center
Acute Myeloid Leukemia (AML)

Paul Shami, MD
Huntsman Cancer Institute at the University of Utah
Acute Myeloid Leukemia (AML)

B. Douglas Smith, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acute Myeloid Leukemia (AML)

Richard M. Stone, MD
Dana-Farber/Brigham and Women's Cancer Center
Acute Myeloid Leukemia (AML)

Martin S. Tallman, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Acute Myeloid Leukemia (AML)

Eunice Wang, MD
Roswell Park Cancer Institute
Acute Myeloid Leukemia (AML)

Frank L. White, MD
St. Jude Children's Research Hospital/University of Tennessee Cancer Institute
Acute Myeloid Leukemia (AML)

 
 
 

*Writing Committee Member

Disclosures for the NCCN Acute Myeloid Leukemia (AML) Guidelines Panel